Vaxcyte Inc
NASDAQ:PCVX

Watchlist Manager
Vaxcyte Inc Logo
Vaxcyte Inc
NASDAQ:PCVX
Watchlist
Price: 46.06 USD 2.7% Market Closed
Market Cap: 6B USD

Vaxcyte Inc
Retained Earnings

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Vaxcyte Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Vaxcyte Inc
NASDAQ:PCVX
Retained Earnings
-$1.4B
CAGR 3-Years
-67%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Retained Earnings
-$14.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Retained Earnings
$35B
CAGR 3-Years
17%
CAGR 5-Years
29%
CAGR 10-Years
48%
No Stocks Found

Vaxcyte Inc
Glance View

Vaxcyte Inc. has carved a niche in the biotechnology industry with its focus on developing next-generation vaccines to tackle some of the most challenging infectious diseases. The company, headquartered in San Carlos, California, leverages its proprietary cell-free protein synthesis platform, XpressCF™, which enables the rapid production of complex proteins at scale. This technology forms the backbone of its vaccine development process, allowing Vaxcyte to bypass traditional cell-based methods that can be both time-consuming and costly. At the core of Vaxcyte's mission is its commitment to addressing unmet medical needs by enhancing the efficacy and safety profiles of vaccines, ultimately aiming to deliver superior alternatives to existing products on the market. Vaxcyte's business model is built on a strategic blend of research and development, partnerships, and intellectual property. The company invests heavily in R&D to advance its pipeline of vaccine candidates, with a particular emphasis on conjugate vaccines targeting bacterial infections such as pneumococcal diseases. Revenue generation is primarily driven through collaborations and licensing agreements with larger pharmaceutical companies that provide upfront payments, milestones, and potential royalties. These partnerships not only validate Vaxcyte’s scientific approach but also furnish the essential capital to sustain its innovative programs and bring its cutting-edge vaccines to market. As Vaxcyte continues to make strides in vaccine development, the company positions itself as a key player in the quest for more effective disease prevention solutions.

PCVX Intrinsic Value
Not Available

See Also

What is Vaxcyte Inc's Retained Earnings?
Retained Earnings
-1.4B USD

Based on the financial report for Dec 31, 2024, Vaxcyte Inc's Retained Earnings amounts to -1.4B USD.

What is Vaxcyte Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-66%

Over the last year, the Retained Earnings growth was -50%. The average annual Retained Earnings growth rates for Vaxcyte Inc have been -67% over the past three years , -66% over the past five years .

Back to Top